semaglutide muscle mass loss (GLP-1) Loss: Body Composition Changes and Findings A phase 2 clinical trial

The medications support your journey, but real change often comes from consistency

The priority here is cost reduction, not financing

Patients utilizing them 75 to 100 percent of the time have greater exposure to drug-specific issues

Compounded GLP-1 Preparations (Not FDA-Approved) Considered only when an FDA-approved alternative is unavailable or clinically inappropriate for an individual patient (503A) or supplied for office use where permitted by law

Cotadutide (MEDI0382) is the most extensively developed dual GLP-1/glucagon receptor agonist, showing significant improvements in glucose control, BW (likely mediated by reduced energy intake rather than increased energy expenditure), hepatic fat, and albuminuria in a small RCT on patients with T2D and overweight or obesity 45,46

We modify our protocols when we know youre on these medications